Aktienanalyse zu Inhibrx Biosciences Inc (INBX)INBXInhibrx Biosciences Inc

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is an engineered tetravalent single domain antibody (sdAb)-based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death. INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40 that provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death. INBRX-106 in Combination with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).

Inhibrx Inc is a good buy right now due to its current price of $123.41, which is significantly below the analyst price targets of $245 and $325. The stock has shown strong momentum with a 5-day change of +19.09% and a 20-day change of +50.41%, indicating positive market sentiment. However, the main risk lies in its negative earnings, with a reported EPS of -2.34 and a forward P/E of 0, reflecting ongoing challenges in profitability.